longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Fortress Biotech

FBIO

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 0.81, above the reasonable range, cheaper than 4.45% of the time in the past 5 years, and the industry ranks 9/602, the industry Median -2.48.

0.81xP/E
$2.51Stock price
$3.10Earnings per share
0.81xP/E
Stock price$2.51Earnings per share$3.10

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-0.93x
Typical range
-3.22x–-0.55x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
P/E ratio
Name/Symbol
REGNUSRegeneron Pharma
18.67x4.10%$80.80B
INCYUSIncyte
15.75x65.04%$25.40B
UTHRUSUnited Therap
16.18x6.53%$21.22B
ASNDUSAscendis Pharmac
18.08x477.31%$15.57B
EXELUSExelixis
16.80x16.46%$14.46B
TGTXUSTG Therap
19.72x65.83%$8.71B
GRFSUSGRIFOLS SA
9.58x42.44%$5.03B
ACADUSAcadia Pharma
12.36x73.45%$4.70B
PURRUSHyperliquid Strategies
10.88x85.25%$2.79B
AUPHUSAurinia Pharma
7.16x54.40%$2.25B
ADMAUSAdma Biologics
12.08x35.42%$2.04B
LKFTUSLakefront Biotherapeutics
2.68x115.23%$1.86B
MGTXUSMeiraGTx
16.11x122.03%$1.27B
VORUSVor BioPharma
2.02x89.77%$1.27B
ABUSUSArbutus Pharma
6.45x533.09%$986.67M
RIGLUSRigel Pharma
2.71x83.91%$871.23M
BVNRYUSBavarian Nordic A/S
3.35x--$802.87M
IRWDUSIronwood Pharma
5.55x715.55%$720.45M
PBYIUSPuma BioTech
18.55x37.70%$495.55M
AGENUSAgenus
3.85x--$353.41M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.